Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.
Background:The aim of this study is to determine whether immunohistochemical (IHC) assessment of Ki67 and p53 improves prognostication of oestrogen receptor-positive (ER+) breast cancer after breast-conserving therapy (BCT). In all, 498 patients with invasive breast cancer from a randomised trial of BCT with or without tumour bed radiation boost were assessed using IHC.Methods:The ER+ tumours were classified as 'luminal A' (LA): ER+ and/or PR+, Ki-67 low, p53-, HER2- or 'luminal B' (LB): ER+ and/or PR+and/or Ki-67 high and/or p53+ and/or HER2+. Kaplan-Meier and Cox proportional hazards methodology were used to ascertain relationships to ispilateral breast tumour recurrence (IBTR), locoregional recurrence (LRR), distant metastasis-free survival (DMFS) and breast cancer-specific survival (BCSS).Results:In all, 73 patients previously LA were re-classified as LB: a greater than four-fold increase (4.6-19.3%) compared with ER, PR, HER2 alone. In multivariate analysis, the LB signature independently predicted LRR (hazard ratio (HR) 3.612, 95% CI 1.555-8.340, P=0.003), DMFS (HR 3.023, 95% CI 1.501-6.087, P=0.002) and BCSS (HR 3.617, 95% CI 1.629-8.031, P=0.002) but not IBTR.Conclusion:The prognostic evaluation of ER+ breast cancer is improved using a marker panel, which includes Ki-67 and p53. This may help better define a group of poor prognosis ER+ patients with a greater probability of failure with endocrine therapy.British Journal of Cancer advance online publication, 28 June 2011; doi:10.1038/bjc.2011.228 www.bjcancer.com.
|Authors||Millar, E. K.; Graham, P. H.; McNeil, C. M.; Browne, L.; O'Toole, S. A.; Boulghourjian, A.; Kearsley, J. H.; Papadatos, G.; Delaney, G.; Fox, C.; Nasser, E.; Capp, A.; Sutherland, R. L.;|
|Publisher Name||BRITISH JOURNAL OF CANCER|
|Published Date||2011-09-01 00:00:00|
|OpenAccess Link||https://publications.gimr.garvan.org.au/download.php?10874_11569/11 Millar BJC__.pdf|